gip glp 1 agonist tirzepatide Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Response in Type 2 Diabetes and Atherosclerosis The dual agonist action of

Elahi D, McAloon-Dyke M, Fukagawa NK, et al

In 2019, the FDA approved Rybelsus (a semaglutide) as the first oral GLP-1 for Type 2 diabetes

Further supporting a direct GLP-1 inhibition of glucagon secretion is the fact that such secretion is not prevented in isolated human islets treated with the insulin receptor antagonist S961 or the somatostatin receptor 2 antagonist CYN154806 [608]

Interpretation is limited by the predominance of potentially overlapped retrospective data and minimal randomized evidence

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, et al

But with the right strategy, you can keep your gut moving while you keep the weight off